Skip to main content
Article thumbnail
Location of Repository

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

By M.C.M. Bunck, M. Diamant, A. Corner, B. Eliasson, J.L. Malloy, R.M. Shaginian, W. Deng, D.M. Kendall, M.R. Taskinen, U. Smith, H. Yki-Jarvinen and R.J. Heine

Abstract

0.0001). beta-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period. A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy. CONCLUSIONS: Exenatide significantly improves beta-cell function during 1 year of treatment compared with titrated insulin glargine. After cessation of both exenatide and insulin glargine therapy, beta-cell function and glycemic control returned to pretreatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therap

Year: 2009
DOI identifier: 10.2337/dc08-1797
OAI identifier: oai:dare.ubvu.vu.nl:1871/20246
Provided by: DSpace at VU
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/1871/202... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.